{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:40:20Z","timestamp":1792176020362,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ucl.2017.04.012","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T04:48:14Z","timestamp":1500094094000},"page":"463-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity"],"prefix":"10.1016","volume":"44","author":[{"given":"Aaron","family":"Kaviani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Khavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3\u20134","key":"10.1016\/j.ucl.2017.04.012_bib1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000353274","article-title":"Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder","volume":"41","author":"Ruffion","year":"2013","journal-title":"Neuroepidemiology"},{"issue":"S3","key":"10.1016\/j.ucl.2017.04.012_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/nau.22636","article-title":"Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder","volume":"33","author":"Haab","year":"2014","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"10.1016\/j.ucl.2017.04.012_bib3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/nau.23027","article-title":"Neurogenic lower urinary tract dysfunction: clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013","volume":"35","author":"Drake","year":"2016","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"10.1016\/j.ucl.2017.04.012_bib4","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.ucl.2017.04.012_bib6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ucl.2017.04.012_bib7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.urology.2012.03.038","article-title":"A modification to augmentation cystoplasty with catheterizable stoma for neurogenic patients: technique and long-term results","volume":"80","author":"Khavari","year":"2012","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2017.04.012_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/nau.22709","article-title":"Functional outcome of supratrigonal cystectomy and augmentation ileocystoplasty in adult patients with refractory neurogenic lower urinary tract dysfunction","volume":"35","author":"Krebs","year":"2016","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.ucl.2017.04.012_bib10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2012.01.051","article-title":"Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity","volume":"61","author":"Behr-Roussel","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2017.04.012_bib12","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.ucl.2017.04.012_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005493.pub3","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","author":"Duthie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ucl.2017.04.012_bib14","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4103\/0366-6999.154318","article-title":"Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis","volume":"128","author":"Zhou","year":"2015","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"10.1016\/j.ucl.2017.04.012_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/nau.22598","article-title":"The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis","volume":"34","author":"Cui","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ucl.2017.04.012_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.urology.2016.10.026","article-title":"Management of overactive bladder with onabotulinumtoxinA: systematic review and meta-analysis","volume":"100","author":"Lopez Ramos","year":"2017","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2017.04.012_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.clinthera.2013.02.020","article-title":"Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States","volume":"35","author":"Carlson","year":"2013","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.ucl.2017.04.012_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/toxins8040088","article-title":"Use of botulinum toxin A in the treatment of lower urinary tract disorders: a review of the literature","volume":"8","author":"Moore","year":"2016","journal-title":"Toxins (Basel)"},{"issue":"Suppl 3","key":"10.1016\/j.ucl.2017.04.012_bib19","first-page":"S26","article-title":"Chapter 5: clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB)","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"issue":"10","key":"10.1016\/j.ucl.2017.04.012_bib20","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/iju.12188","article-title":"Botulinum toxin treatment for bladder dysfunction","volume":"20","author":"Santos-Silva","year":"2013","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2017.04.012_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2017.04.012_bib22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.rehab.2014.05.004","article-title":"OnabotulinumtoxinA and multiple sclerosis","volume":"57","author":"Schurch","year":"2014","journal-title":"Ann Phys Rehabil Med"},{"issue":"6","key":"10.1016\/j.ucl.2017.04.012_bib23","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.ucl.2017.04.012_bib24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/nau.22376","article-title":"OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity","volume":"32","author":"Rovner","year":"2013","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","article-title":"Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis","volume":"81","author":"Kennelly","year":"2013","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.juro.2016.04.046","article-title":"Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment","volume":"196","author":"Rovner","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2017.04.012_bib27","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00345-012-0984-0","article-title":"An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity","volume":"31","author":"Apostolidis","year":"2013","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/sc.2015.143","article-title":"Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity","volume":"54","author":"Hui","year":"2016","journal-title":"Spinal Cord"},{"issue":"6","key":"10.1016\/j.ucl.2017.04.012_bib29","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","article-title":"Botulinum toxin-A injections into neurogenic overactive bladder\u2013to include or exclude the trigone? A prospective, randomized, controlled trial","volume":"184","author":"Abdel-Meguid","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2017.04.012_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrurol.2016.53","article-title":"Management of neurogenic bladder in patients with multiple sclerosis","volume":"13","author":"Phe","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ucl.2014.04.004","article-title":"Urodynamics in the evaluation of the patient with multiple sclerosis: when are they helpful and how do we use them?","volume":"41","author":"Dillon","year":"2014","journal-title":"Urol Clin North Am"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/nau.22670","article-title":"The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis","volume":"35","author":"Khalaf","year":"2016","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"10.1016\/j.ucl.2017.04.012_bib33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.ucl.2017.04.012_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/nau.22757","article-title":"Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity","volume":"35","author":"Chartier-Kastler","year":"2016","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.ucl.2017.04.012_bib35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21209","article-title":"Botulinum injections for the treatment of bladder symptoms of multiple sclerosis","volume":"62","author":"Kalsi","year":"2007","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.ucl.2017.04.012_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006008.pub3","article-title":"Intermittent catheterisation for long-term bladder management","author":"Prieto","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ucl.2017.04.012_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/1352458516633903","article-title":"Urinary tract infections in multiple sclerosis","volume":"22","author":"Phe","year":"2016","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.ucl.2017.04.012_bib38","first-page":"67","article-title":"Urinary tract infections may trigger relapse in multiple sclerosis","volume":"19","author":"Metz","year":"1998","journal-title":"Axone"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13813450701531227","article-title":"Systemic infections in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"113","author":"Tauber","year":"2007","journal-title":"Arch Physiol Biochem"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.eururo.2016.03.052","article-title":"More than 15 years of experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: lessons to be learned","volume":"70","author":"Leitner","year":"2016","journal-title":"Eur Urol"},{"issue":"Pt A","key":"10.1016\/j.ucl.2017.04.012_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2015.07.333","article-title":"Use of botulinum toxin for genitourinary conditions: what is the evidence?","volume":"107","author":"da Silva","year":"2015","journal-title":"Toxicon"},{"issue":"8","key":"10.1016\/j.ucl.2017.04.012_bib42","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.apmr.2013.04.011","article-title":"Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury","volume":"94","author":"Mehta","year":"2013","journal-title":"Arch Phys Med Rehabil"},{"issue":"18","key":"10.1016\/j.ucl.2017.04.012_bib43","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1089\/neu.2015.4278","article-title":"Reduction in bladder-related autonomic dysreflexia after onabotulinumtoxinA treatment in spinal cord injury","volume":"33","author":"Fougere","year":"2016","journal-title":"J Neurotrauma"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1464-410X.2011.010362.x","article-title":"Effects of intravesical onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia after spinal cord injury: role of nerve growth factor","volume":"109","author":"Elkelini","year":"2012","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2017.04.012_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/nau.22764","article-title":"A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders","volume":"35","author":"Sakakibara","year":"2016","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"10.1016\/j.ucl.2017.04.012_bib46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11934-014-0426-1","article-title":"Botulinum toxin A's expanding role in the management of pediatric lower urinary tract dysfunction","volume":"15","author":"Hassouna","year":"2014","journal-title":"Curr Urol Rep"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jpurol.2009.01.005","article-title":"Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"5","author":"Game","year":"2009","journal-title":"J Pediatr Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/nau.23025","article-title":"Outcomes of intra-detrusor injections of botulinum toxin in patients with spina bifida: a systematic review","volume":"36","author":"Hascoet","year":"2017","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2013.09.017","article-title":"OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease","volume":"83","author":"Anderson","year":"2014","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12894-016-0174-2","article-title":"Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson's disease","volume":"16","author":"Knupfer","year":"2016","journal-title":"BMC Urol"},{"issue":"8","key":"10.1016\/j.ucl.2017.04.012_bib51","doi-asserted-by":"crossref","first-page":"e105989","DOI":"10.1371\/journal.pone.0105989","article-title":"Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ucl.2017.04.012_bib52","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.parkreldis.2010.06.006","article-title":"Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease","volume":"16","author":"Kulaksizoglu","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib53","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","article-title":"Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder","volume":"186","author":"Giannantoni","year":"2011","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2017.04.012_bib54","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","article-title":"Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy","volume":"182","author":"Giannantoni","year":"2009","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2017.04.012_bib55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.urology.2005.08.016","article-title":"Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions","volume":"67","author":"Kuo","year":"2006","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib56","doi-asserted-by":"crossref","first-page":"27.e1-4","DOI":"10.1016\/j.jpurol.2014.08.009","article-title":"Botulinum injection is useless on fibrotic neuropathic bladders","volume":"11","author":"Tiryaki","year":"2015","journal-title":"J Pediatr Urol"},{"issue":"4","key":"10.1016\/j.ucl.2017.04.012_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4111\/kju.2014.55.4.281","article-title":"Intradetrusor injections of onabotulinum toxin-A in children with urinary incontinence due to neurogenic detrusor overactivity refractory to antimuscarinic treatment","volume":"55","author":"Tarcan","year":"2014","journal-title":"Korean J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/toxins5010016","article-title":"Onabotulinumtoxin A for treating overactive\/poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele","volume":"5","author":"Marte","year":"2013","journal-title":"Toxins (Basel)"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5173\/ceju.2012.03.art12","article-title":"Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children","volume":"65","author":"Zeino","year":"2012","journal-title":"Cent European J Urol"},{"issue":"8","key":"10.1016\/j.ucl.2017.04.012_bib60","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/nau.21124","article-title":"Repeated botulinum-a toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele","volume":"30","author":"Horst","year":"2011","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.urology.2009.09.087","article-title":"Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods","volume":"76","author":"Safari","year":"2010","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2017.04.012_bib62","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.juro.2010.01.058","article-title":"Total endoscopic and anal irrigation management approach to noncompliant neuropathic bladder in children: a good alternative","volume":"184","author":"Neel","year":"2010","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2017.04.012_bib63","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1445-2197.2009.05129.x","article-title":"Study of botulinum toxin A in neurogenic bladder due to spina bifida in children","volume":"80","author":"Deshpande","year":"2010","journal-title":"ANZ J Surg"},{"issue":"5","key":"10.1016\/j.ucl.2017.04.012_bib64","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.urology.2006.05.056","article-title":"Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele","volume":"68","author":"Kajbafzadeh","year":"2006","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib65","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0022-5347(05)00400-3","article-title":"Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele","volume":"175","author":"Altaweel","year":"2006","journal-title":"J Urol"},{"issue":"2, Part 1","key":"10.1016\/j.ucl.2017.04.012_bib66","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.ju.0000108892.35041.2d","article-title":"Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia","volume":"171","author":"Riccabona","year":"2004","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.04.012_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0090-4295(01)01641-7","article-title":"Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results","volume":"59","author":"Schulte-Baukloh","year":"2002","journal-title":"Urology"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014317300307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014317300307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:35:24Z","timestamp":1758807324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014317300307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0094014317300307"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2017.04.012","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2017.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}